Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06161896Recruiting

Characterization and Clinical Impact of the Gut Microbiota in Lymphoma

Role: lead

NCT04630275Completed

Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality-Obs

Role: lead

NCT04492553Phase 2Completed

Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality

Role: lead

NCT03939234Phase 2Completed

Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.

Role: lead

NCT03381768Phase 1Completed

Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma

Role: lead

All 5 trials loaded